Reading time: < 1 minute
An experimental vaccine developed using non-infectious virus-like particles (VLP) has protected macaques and mice against chikungunya virus, a mosquito-borne pathogen that has infected millions of people in Africa and Asia and causes debilitating pain, researchers at the National Institutes of Health have found. Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) developed the vaccine because there is no vaccine or treatment for chikungunya virus infection.
HHS, NIH Take Steps to Enhance Transparency, Public Access to Clinical Trial Results
Ebola Outbreak Increases Pressure to Start Vaccine Trials
Disorganized Patches in the Brain Suggest Prenatal Origin of Autism
About the Author
